查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲影像導引藥物傳輸市場：依技術類型、應用、最終用戶和國家 - 分析與預測（2025年至2035年）
市場調查報告書
商品編碼
1847082

歐洲影像導引藥物傳輸市場：依技術類型、應用、最終用戶和國家 - 分析與預測（2025年至2035年）

Europe Image-Guided Drug Delivery Market: Focus on Technology Type, Application, End User, and Country Analysis - Analysis and Forecast, 2025-2035
出版日期: | 出版商: BIS Research | 英文 65 Pages | 商品交期: 1-5個工作天內

價格

預計到2035年，歐洲影像導引藥物傳輸市場規模將達到 2.841億美元，高於2024年的1,370萬美元，在2025-2035年預測期內的年複合成長率為 32.01%。

在歐洲，影像導引藥物傳遞（IGDD）採用先進且精準的微創技術，將治療藥物直接輸送至腫瘤和神經系統等患病區域。這種創新策略代表著從傳統的全身性治療轉變為更針對患者、更局部、更安全的方法的轉變。 IGDD 利用機器人技術和人工智慧導航，將導管和套管等專用輸送工具與 MRI、CT 和超音波等成像平台相結合，使醫生能夠以驚人的精度實施化療、基因治療和細胞療法。這項技術改善了治療效果，降低了全身毒性，加快了康復速度，並最大限度地提高了醫療效益，使 IGDD 成為歐洲精準醫療的重要組成部分。

主要市場統計資料
預測期 2025-2035
2025年評估 1770萬美元
2035年的預測 2.841億美元
年複合成長率 32.01%

市場介紹

IGDD 系統的使用歐洲各地不斷擴展，先進成像藥物傳輸技術的開發正推動歐洲市場的爆炸性成長。透過將藥物精準輸送至腫瘤或腦區等特定疾病部位，這些設備可以降低全身毒性並改善患者預後。歐洲對標靶藥物輸送和精準醫療日益成長的需求推動了對結合 MRI、CT、PET 和超音波影像與微創治療的尖端藥物輸送平台的投資。

在歐洲，影像導引藥物傳遞應用主要集中在腫瘤科、神經科和創傷治療領域，由於癌症發生率上升，腫瘤科的應用尤其突出。歐洲人口老化、慢性病發病率上升以及影像引導藥物輸送技術的不斷改進，都促進了市場的擴張。此外，由於政府對醫療創新的資金投入和監管支持，IGDD 系統在歐洲的普及速度更快，使其成為下一代精準醫療解決方案的關鍵組成部分。

德國、法國和英國憑藉其在精準靶向給藥技術方面的巨額研發投入和完善的醫療基礎設施，在歐洲影像引導給藥產業中佔據主導地位。由於醫療保健管道的改善和醫療意識的提升，東歐新興國家對影像引導給藥系統的採用也日益增加。然而，高昂的前期成本、複雜的法規、技術限制以及對患者資料隱私的擔憂等因素，仍然是市場滲透和廣泛應用的阻礙。

預計未來十年，歐洲靶向藥物輸送市場將迎來強勁成長，這得益於持續的技術進步以及對個人化藥物輸送日益成長的關注。主導導航、機器人技術和影像技術的整合將提高治療精準度，縮短復原時間，並最佳化醫療資源，使歐洲成為下一代精準醫療和標靶藥物輸送解決方案的領導者。

市場區隔

細分 1：依技術類型

  • 藥物輸送系統
  • 影像引導平台

細分2：依應用

  • 腫瘤學
  • 神經病學
  • 其他

細分 3：依最終用戶

  • 醫院
  • 製藥和生物技術公司
  • 委外研發機構（CRO）
  • 科學研究院所及大學

細分4：依地區

  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他

歐洲影像導引藥物傳輸市場趨勢、促進因素與挑戰

市場趨勢

  • 技術進步：MRI、CT、PET 和超音波等顯像模式與藥物傳遞系統的結合提高了治療的精確度和療效，特別是在腫瘤學和神經病學領域。
  • 微創手術：人們越來越傾向於微創手術，並且擴大採用影像引導療法，縮短恢復時間並改善患者的治療效果。
  • 個人化醫療：向個人化治療計劃的轉變推動針對個人患者情況的IGDD 系統的開發和採用。
  • 監管支援：歐洲監管機構為創新藥物輸送技術的核准提供了明確的途徑，促進了市場成長。

市場促進因素

  • 慢性病發病率上升：癌症和神經系統疾病等疾病的發生率不斷上升，推動了對有針對性和有效治療方案的需求。
  • 成像技術的進步：顯像模式的不斷改進提高了 IGDD 系統的準確性和可靠性，使其對醫療保健提供者更具吸引力。
  • 人口老化：歐洲人口老化和與老齡化相關的疾病發病率上升推動了對先進藥物輸送解決方案的需求。
  • 醫療保健基礎設施：歐洲擁有發達的醫療基礎設施和高水準的醫療專業知識，引進了先進的藥物輸送系統。
  • 政府措施：政府的支持性政策和對醫學研究的資助加速 IGDD 技術的開發和應用。

市場挑戰

  • 高成本：IGDD 系統的初始投資和維護成本可能很高，限制了其使用，尤其是在較小的醫療機構中。
  • 監管障礙：醫療設備和藥物輸送系統複雜的監管環境可能會減緩市場進入和採用的速度。
  • 技術限制：整合影像處理和藥物傳輸技術所帶來的挑戰以及設備校準和標準化問題可能會影響 IGDD 系統的有效性。
  • 患者意識：患者對 IGDD 治療的認知和理解有限可能會阻礙他們接受和利用這些先進的治療方法。
  • 資料隱私問題：在藥物輸送中使用影像資料引發了對病患資料隱私和安全的擔憂，需要嚴格遵守資料保護條例。

產品/創新策略：本報告深入探討了影像導引藥物傳輸領域的最新技術進步，使公司能夠推動創新並開發出滿足市場需求的尖端產品。

成長/行銷策略：透過提供全面的市場分析和識別關鍵的成長機會，公司能夠獲得制定有針對性的行銷策略和有效擴大其市場佔有率的知識。

競爭策略：透過對競爭格局的徹底分析，了解競爭對手的優勢和劣勢，並幫助制定有效的策略以在市場上獲得競爭優勢。

監管和合規策略：提供有關不斷發展的法律規範、核准和行業指南的最新資訊，以使公司能夠保持合規並加速新型圖像引導藥物輸送解決方案的市場進入。

投資和業務擴大策略：透過分析市場趨勢、資金籌措模式和合作機會，幫助公司做出明智的投資決策並確定業務成長的潛在併購機會。

主要市場參與企業和競爭對手的摘要

公司簡介是根據從主要專家收集的意見以及對公司覆蓋範圍、產品系列和市場滲透率的分析而選擇的。

該市場的一些知名參與者包括：

  • Renishaw plc.
  • Neurochase
  • Koninklijke Philips NV

目錄

執行摘要

第1章 市場：產業展望

  • 競爭格局
  • 產業展望
    • 趨勢、促進因素、挑戰與機會：現狀與未來影響評估，2024-2035
    • 市場趨勢
    • 影像導引藥物傳遞的進展
    • 影像導引藥物傳遞的未來方向和新興技術
  • 市場動態

第2章 區域

  • 區域摘要
  • 歐洲
    • 區域概況
    • 市場成長動力
    • 成長抑制因素
    • 依技術類型
    • 依用途
    • 依最終用戶
    • 依國家

第3章 市場-公司簡介

  • 公司簡介
    • Renishaw plc.
    • Neurochase
    • Koninklijke Philips NV

第4章 調查方法

Product Code: BHL3344SS

This report can be delivered in 2 working days.

Introduction to Europe Image-Guided Drug Delivery Market

The Europe image-guided drug delivery market is projected to reach $284.1 million by 2035 from $13.7 million in 2024, growing at a CAGR of 32.01% during the forecast period 2025-2035. Therapeutics are delivered directly to illness areas, such as tumors and neurological regions, in Europe through Image-Guided Drug Delivery (IGDD), which uses sophisticated, precision-focused, minimally invasive procedures. This novel strategy represents a change from traditional systemic treatments to more patient-specific, localized, and safe approaches. With the use of robots and AI-guided navigation, IGDD enables physicians to deliver chemotherapeutics, gene therapies, and cell-based treatments with remarkable precision by fusing specialized delivery tools like catheters and cannulae with imaging platforms like MRI, CT, and ultrasound. The technique improves treatment results, lowers systemic toxicity, speeds up recuperation, and maximizes healthcare effectiveness, making IGDD a crucial component of Europe's precision medicine scene.

KEY MARKET STATISTICS
Forecast Period2025 - 2035
2025 Evaluation$17.7 Million
2035 Forecast$284.1 Million
CAGR32.01%

Market Introduction

The growing use of IGDD systems throughout Europe and developments in sophisticated imaging drug delivery technologies are fueling the market's explosive expansion in Europe. By precisely delivering medications to specific disease sites, such as tumors and brain areas, these devices lower systemic toxicity and enhance patient outcomes. Investments in cutting-edge drug delivery platforms that combine MRI, CT, PET, and ultrasound imaging with minimally invasive treatments are being driven by the rising need for targeted medication delivery and precision medicine in Europe.

In Europe, image-guided drug delivery applications are predominantly seen in oncology, neurology, and wound healing, with oncology leading due to rising cancer prevalence. The aging of Europe's population, the rise in chronic illnesses, and continuous improvements in imaging-guided drug delivery technologies all contribute to the market's expansion. Additionally, IGDD systems are being adopted more quickly in Europe thanks to government financing for healthcare innovation and favorable regulatory support, making these technologies a crucial component of next-generation precision medicine solutions.

With substantial R&D expenditures in precision-targeted drug delivery technology and established healthcare infrastructure, Germany, France, and the United Kingdom dominate the European image-guided drug delivery industry. Because of increased access to and awareness of healthcare, emerging economies in Eastern Europe are progressively implementing IGDD systems. However, obstacles including high upfront costs, complicated regulations, technical constraints, and privacy concerns about patient data still hinder market penetration and broad adoption.

The Europe IGDD market is projected to achieve strong growth over the next decade, driven by continuous technological advancements and the increasing emphasis on personalized drug delivery. Integrating AI-driven navigation, robotics, and imaging technologies will enhance therapeutic precision, reduce recovery times, and optimize healthcare resources, positioning Europe as a leader in next-generation precision medicine and targeted drug delivery solutions.

Market Segmentation:

Segmentation 1: By Technology Type

  • Drug-Delivery Systems
  • Image-Guided Platforms

Segmentation 2: By Application

  • Oncology
  • Neurology
  • Others

Segmentation 3: By End User

  • Hospitals
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Research Institutes & Universities

Segmentation 4: By Region

  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe

Europe Image-Guided Drug Delivery Market Trends, Drivers and Challenges

Market Trends

  • Technological Advancements: Integration of imaging modalities such as MRI, CT, PET, and ultrasound with drug delivery systems is enhancing the precision and efficacy of treatments, particularly in oncology and neurology.
  • Minimally Invasive Procedures: There is a growing preference for minimally invasive techniques, leading to increased adoption of image-guided therapies that offer reduced recovery times and improved patient outcomes.
  • Personalized Medicine: The shift towards personalized treatment plans is fostering the development and adoption of IGDD systems tailored to individual patient profiles.
  • Regulatory Support: European regulatory bodies are providing clearer pathways for the approval of innovative drug delivery technologies, facilitating market growth.

Market Drivers

  • Rising Incidence of Chronic Diseases: The increasing prevalence of conditions such as cancer and neurological disorders is driving demand for targeted and effective treatment options.
  • Advancements in Imaging Technologies: Continuous improvements in imaging modalities are enhancing the accuracy and reliability of IGDD systems, making them more appealing to healthcare providers.
  • Aging Population: Europe's aging demographic is contributing to a higher incidence of age-related diseases, thereby increasing the need for advanced drug delivery solutions.
  • Healthcare Infrastructure: Well-established healthcare infrastructure and a high level of medical expertise in Europe are conducive to the adoption of advanced drug delivery systems.
  • Government Initiatives: Supportive government policies and funding for medical research are accelerating the development and implementation of IGDD technologies.

Market Challenges

  • High Costs: The initial investment and maintenance costs of IGDD systems can be prohibitive, limiting their accessibility, especially in smaller healthcare facilities.
  • Regulatory Hurdles: Navigating the complex regulatory landscape for medical devices and drug delivery systems can delay market entry and adoption.
  • Technical Limitations: Challenges related to the integration of imaging and drug delivery technologies, as well as issues with device calibration and standardization, can impact the effectiveness of IGDD systems.
  • Patient Awareness: Limited patient awareness and understanding of IGDD therapies can hinder acceptance and utilization of these advanced treatment options.
  • Data Privacy Concerns: The use of imaging data in drug delivery raises concerns regarding patient data privacy and security, necessitating stringent compliance with data protection regulations.

How can this report add value to an organization?

Product/Innovation Strategy: The report offers in-depth insights into the latest technological advancements in Image-Guided Drug Delivery, enabling organizations to drive innovation and develop cutting-edge products tailored to market needs.

Growth/Marketing Strategy: By providing comprehensive market analysis and identifying key growth opportunities, the report equips organizations with the knowledge to craft targeted marketing strategies and expand their market presence effectively.

Competitive Strategy: The report includes a thorough competitive landscape analysis, helping organizations understand their competitors' strengths and weaknesses and allowing them to strategize effectively to gain a competitive edge in the market.

Regulatory and Compliance Strategy: It provides updates on evolving regulatory frameworks, approvals, and industry guidelines, ensuring organizations stay compliant and accelerate market entry for new Image-Guided Drug Delivery

Investment and Business Expansion Strategy: By analyzing market trends, funding patterns, and partnership opportunities, the report assists organizations in making informed investment decisions and identifying potential M&A opportunities for business growth.

Key Market Players and Competition Synopsis

Profiled companies have been selected based on inputs gathered from primary experts, as well as analyzing company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

  • Renishaw plc.
  • Neurochase
  • Koninklijke Philips N.V.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

  • 1.1 Competitive Landscape
  • 1.2 Industry Outlook
    • 1.2.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
    • 1.2.2 Market Trends
      • 1.2.2.1 Integration of Imaging with Targeted Drug Delivery
    • 1.2.3 Advancements in Image-Guided Drug Delivery
    • 1.2.4 Future Direction and Emerging Technologies in Image-Guided Drug Delivery
  • 1.3 Market Dynamics
    • 1.3.1 Impact Analysis
    • 1.3.2 Market Driver
      • 1.3.2.1 Increased Demand for Personalized Medicine
      • 1.3.2.2 Rising Prevalence of Chronic Diseases
      • 1.3.2.3 Technological Advancements in Image-Guided Drug Delivery
    • 1.3.3 Market Restraint
      • 1.3.3.1 High Acquisition Cost of the Instruments
    • 1.3.4 Market Opportunity
      • 1.3.4.1 Integration of Artificial Intelligence in Image-Guided Drug Delivery

2 Region

  • 2.1 Regional Summary
  • 2.2 Europe
    • 2.2.1 Regional Overview
    • 2.2.2 Driving Factors for Market Growth
    • 2.2.3 Factors Challenging the Market
    • 2.2.4 By Technology Type
    • 2.2.5 By Application
    • 2.2.6 By End User
    • 2.2.7 By Country
      • 2.2.7.1 U.K.
    • 2.2.8 By Technology Type
    • 2.2.9 By Application
    • 2.2.10 By End User
      • 2.2.10.1 Germany
    • 2.2.11 By Technology Type
    • 2.2.12 By Application
    • 2.2.13 By End User
      • 2.2.13.1 France
    • 2.2.14 By Technology Type
    • 2.2.15 By Application
    • 2.2.16 By End User
      • 2.2.16.1 Italy
    • 2.2.17 By Technology Type
    • 2.2.18 By Application
    • 2.2.19 By End User
      • 2.2.19.1 Spain
    • 2.2.20 By Technology Type
    • 2.2.21 By Application
    • 2.2.22 By End User
      • 2.2.22.1 Rest-of-Europe
    • 2.2.23 By Technology Type
    • 2.2.24 By Application
    • 2.2.25 By End User

3 Markets - Company Profiles

  • 3.1 Company Profiles
    • 3.1.1 Renishaw plc.
      • 3.1.1.1 Overview
      • 3.1.1.2 Pipeline Product Portfolio
      • 3.1.1.3 Top Competitors
      • 3.1.1.4 Target Customers
      • 3.1.1.5 Key Personnel
      • 3.1.1.6 Analyst View
      • 3.1.1.7 Renishaw plc., Revenue ($Million), 2022-2024
    • 3.1.2 Neurochase
      • 3.1.2.1 Overview
      • 3.1.2.2 Pipeline Product Portfolio
      • 3.1.2.3 Top Competitors
      • 3.1.2.4 Target Customers
      • 3.1.2.5 Key Personnel
      • 3.1.2.6 Analyst View
    • 3.1.3 Koninklijke Philips N.V.
      • 3.1.3.1 Overview
      • 3.1.3.1 Top Products/Product Portfolio
      • 3.1.3.2 Top Competitors
      • 3.1.3.3 Target Customers
      • 3.1.3.4 Key Personnel
      • 3.1.3.5 Analyst View

4 Research Methodology

  • 4.1 Data Sources
    • 4.1.1 Primary Data Sources
    • 4.1.2 Secondary Data Sources
    • 4.1.3 Data Triangulation
  • 4.2 Market Estimation and Forecast

List of Figures

  • Figure 1: Europe Image-Guided Drug Delivery Market (by Scenario), $Million, 2024, 2030, and 2035
  • Figure 2: Europe Image-Guided Drug Delivery Market, 2024 and 2035
  • Figure 3: Europe Image-Guided Drug Delivery Market Snapshot
  • Figure 4: Image-Guided Drug Delivery Market, $Million, 2024 and 2035
  • Figure 5: Europe Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024, 2030, and 2035
  • Figure 6: Europe Image-Guided Drug Delivery Market (by Application), $Million, 2024, 2030, and 2035
  • Figure 7: Europe Image-Guided Drug Delivery Market (by End User), $Million, 2024, 2030, and 2035
  • Figure 8: Europe Image-Guided Drug Delivery Market Segmentation
  • Figure 9: U.K. Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 10: Germany Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 11: France Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 12: Italy Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 13: Spain Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 14: Rest-of-Europe Image-Guided Drug Delivery Market, $Million, 2024-2035
  • Figure 15: Data Triangulation
  • Figure 16: Top-Down and Bottom-Up Approach
  • Figure 17: Assumptions and Limitations

List of Tables

  • Table 1: Market Snapshot
  • Table 2: Image-Guided Drug Delivery Market (by Region), $Million, 2024-2035
  • Table 3: Europe Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 4: Europe Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 5: Europe Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 6: U.K. Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 7: U.K. Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 8: U.K. Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 9: Germany Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 10: Germany Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 11: Germany Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 12: France Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 13: France Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 14: France Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 15: Italy Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 16: Italy Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 17: Italy Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 18: Spain Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 19: Spain Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 20: Spain Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035
  • Table 21: Rest-of-Europe Image-Guided Drug Delivery Market (by Technology Type), $Million, 2024-2035
  • Table 22: Rest-of-Europe Image-Guided Drug Delivery Market (by Application), $Million, 2024-2035
  • Table 23: Rest-of-Europe Image-Guided Drug Delivery Market (by End User), $Million, 2024-2035